Expert Outlook: Glaukos Through The Eyes Of 10 Analysts
In the preceding three months, 10 analysts have released ratings for Glaukos (NYSE:GKOS), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $134.8, a high estimate of $160.00, and a low estimate of $116.00. Observing a 10.95% increase, the current average has risen from the previous average price target of $121.50.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Glaukos by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ryan Zimmerman | BTIG | Maintains | Buy | $131.00 | $131.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $131.00 | $123.00 |
| Thomas Stephan | Stifel | Raises | Buy | $160.00 | $115.00 |
| David Saxon | Needham | Maintains | Buy | $125.00 | $125.00 |
| George Sellers | Stephens & Co. | Raises | Overweight | $145.00 | $115.00 |
| Ryan Zimmerman | BTIG | Maintains | Buy | $116.00 | $116.00 |
| Danielle Antalffy | UBS | Raises | Buy | $145.00 | $140.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $145.00 | $120.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $125.00 | $113.00 |
| David Saxon | Needham | Raises | Buy | $125.00 | $117.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Glaukos's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Glaukos analyst ratings.
All You Need to Know About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos: A Financial Overview
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Glaukos showcased positive performance, achieving a revenue growth rate of 38.14% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -12.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Glaukos's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.